(Total Views: 162)
Posted On: 03/24/2023 11:08:36 AM
Post# of 26763
Great Partnership News with High Times Out Yesterday!
Lucy Scientific Discovery Announces Partnership with High Times® to Develop and Distribute a New Line of Psychoactive Products
‘Mindful by Lucy’
March 23, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “The Company”) (NASDAQ:LSDI), a leading NASDAQ-listed psychedelic drug manufacturer, announced today the launch of a new line of unscheduled psychoactive compounds that will be available for sale throughout the United States, and where permitted throughout the rest of the world.
The first line in the new family of brands contains Amanita Muscaria mushrooms, a psychoactive adaptogen. The product leverages the compounds of these mushrooms, and a proprietary blend of other natural functional ingredients, to create a transformative experience for consumers worldwide. This product line is named ‘Mindful by Lucy’.
Lucy Scientific will produce Mindful with High Times, through a strategic partnership with High Times Holding Corp., the parent company of High Times®, the most well-known brand in cannabis. This collaboration aims to distribute and market the products initially through High Times' websites and social channels which reach over 10 million people across their owned and operated properties and social media accounts.
With a product launch targeted for Q2 2023, this new line is well-positioned to capitalize on the growing market for psychoactive alternatives, which Forbes predicts will double to over $5 billion in gross sales by 2025.
Lucy and High Times entered into a strategic investment agreement in January whereby Lucy received $2.5 million in advertising credits that will help launch the new brand into market through High Times channels and experiential events.
Chris McElvany, Chief Executive Officer of Lucy Scientific Discovery Inc., stated, “As awareness and acceptance of alternative treatments for various conditions, such as PTSD, anxiety disorders, and depression, continue to grow, adaptogens are emerging as a leading therapeutic remedy. This partnership between Lucy and High Times will enable the two companies to expand the reach of Lucy’s products and promote the potential health benefits to a broader audience.”
We would like to see a clean break above the 20 DMA at $1.63/share.
Recent IPO report on the first psychedelics manufacturing company to be listed on NASDAQ!
Lucy Scientific Discovery Inc. (NASDAQ: LSDI)
Hot sector, building momentum, low float, great setup
Current price $1.39/share as of market close 03/22/23
Public Float 10.15M Shares (Source: Yahoo Finance)
Range Since Inception $1.12 - $4.00/share
About Lucy
Lucy Scientific Discovery Inc. is a Nasdaq-listed (NASDAQ: LSDI) licensed producer of compounds for medicinal products. As granted by Health Canada’s Office of Controlled Substances, Lucy maintains a Controlled Drugs and Substances Dealer’s License, under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s License. A Dealer’s License authorizes LSDI to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors.
Here is What Lucy Offers (Source: https://www.lucyscientific.com/)
API and Target Formulation Production
By leveraging various scalable production methods, Lucy is uniquely positioned to effectively support current and future market needs at competitive prices.
Lucy's use of efficient and strategic manufacturing practices ensure a consistent and stable supply of the highest quality products from lab- to consumer-scale.
Research, Development and Commercialization Support
We will work directly with researchers and finished product manufacturers in a controlled and collaborative environment to facilitate healthy market growth.
Our team aims to maximize your probability of success while minimizing the time and costs required to achieve your goals.
Lucy (LSDI) has announced multiple breaking developments since its IPO last month.
LSDI is “focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry”.
The company’s mission is to make their “products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs including various mental health and addiction disorders”.
As the company stated in a recent press release:
“The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options.”
In addition, as the company explained:
“We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States,” said Chris McElvany, the Company’s CEO.
LSDI is “a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies”.
Furthermore, “The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B”.
The company’s team “is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.”
In addition, the company’s “executive team brings deep experience in the development and commercialization of products featuring controlled substances as well as the navigation of regulatory structures applicable to these products”.
LSDI’s target customers “include an increasing number of the leading universities, hospitals and other public, private, and government institutions throughout the world that have launched research programs to conduct clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances”.
Recently, the company achieved multiple milestones.
On February 13, the company announced:
“Lucy Scientific Discovery Announces Closing of its $7.5 Million Initial Public Offering”
In addition, the company announced:
“Lucy Scientific Discovery to Ring Nasdaq Closing Bell Today in Celebration of its IPO”
Here are the company’s comments from this press release:
“We are excited to celebrate this victory at Nasdaq's iconic bell ringing ceremony, as today marks an important milestone for the Company,” said Chris McElvany, the Company’s CEO. “We are pleased to celebrate many months of hard work and team effort that led to the successful completion of our IPO. Seeing Lucy, a pioneer in psychedelics manufacturing, take the next step in its development by becoming the first psychedelics manufacturing company to be listed on NASDAQ is a huge accomplishment. This milestone marks a significant step in the company's growth and plans for expansion. We look forward to the opportunities ahead of us to continue working on improving mental health and finding sustainable solutions for treatment.”
Afterwards, the company announced another big accomplishment:
“Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin Following Initial Delivery of DMT and 5-MeO-DMT to Hadassah BrainLabs”
Here are the company’s comments from this press release:
“This first commercial sale of psilocybin marks a key operational milestone for the company as we shift from pre revenue to revenue producing, and are excited about further opportunities ahead,” said Lucy’s CEO Chris McElvany. “This transaction establishes Lucy’s ability to supply the global psychedelic community with compounds and services. Not only will it strengthen our relationship with the researchers at Hadassah-Hebrew University Medical Center, whose research helps lay the academic foundations indicating the potential of psychedelics, it will lead to the improvement of lives of millions of people around the world.”
Most recently, on Friday, the company announced another significant development:
“Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities”
As the company further explains:
LSDI “partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies”.
Furthermore:
“By leveraging Pramantha Group's expertise in identifying and capturing strategic funding and contract opportunities, Lucy Scientific is well-positioned to compete for and secure key government contracts and grants. With access to these funds, Lucy Scientific will be able to expand its drug manufacturing capabilities and contribute to the country's healthcare needs.”
Here are some of the company’s comments from this press release:
"Our partnership with Pramantha Group will help us navigate the complex landscape of government contracts and grants and identify the right opportunities to support our growth and contribute to the country's healthcare needs," said Lucy Scientific Discovery’s CEO Chris McElvany. "We are excited to work with Pramantha Group to enhance our drug manufacturing capabilities and play a key role in securing the domestic drug supply. Pramantha has a proven track record and a commitment to excellence that makes it an ideal partner for Lucy as we look to grow our operations."
LSDI has multiple potential catalysts favoring a future of increased growth.
The chart is flashing oversold with an RSI of 35.34
A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD $6,859.95 million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027.
It is important to note that approximately 70% of the psychedelics market is attributable to psychedelics manufacturers.
Full Analysis and Disclosure: https://mailchi.mp/broadstreetalerts/lsdi-lic...s-94477?e=[UNIQID]
Lucy Scientific Discovery Announces Partnership with High Times® to Develop and Distribute a New Line of Psychoactive Products
‘Mindful by Lucy’
March 23, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “The Company”) (NASDAQ:LSDI), a leading NASDAQ-listed psychedelic drug manufacturer, announced today the launch of a new line of unscheduled psychoactive compounds that will be available for sale throughout the United States, and where permitted throughout the rest of the world.
The first line in the new family of brands contains Amanita Muscaria mushrooms, a psychoactive adaptogen. The product leverages the compounds of these mushrooms, and a proprietary blend of other natural functional ingredients, to create a transformative experience for consumers worldwide. This product line is named ‘Mindful by Lucy’.
Lucy Scientific will produce Mindful with High Times, through a strategic partnership with High Times Holding Corp., the parent company of High Times®, the most well-known brand in cannabis. This collaboration aims to distribute and market the products initially through High Times' websites and social channels which reach over 10 million people across their owned and operated properties and social media accounts.
With a product launch targeted for Q2 2023, this new line is well-positioned to capitalize on the growing market for psychoactive alternatives, which Forbes predicts will double to over $5 billion in gross sales by 2025.
Lucy and High Times entered into a strategic investment agreement in January whereby Lucy received $2.5 million in advertising credits that will help launch the new brand into market through High Times channels and experiential events.
Chris McElvany, Chief Executive Officer of Lucy Scientific Discovery Inc., stated, “As awareness and acceptance of alternative treatments for various conditions, such as PTSD, anxiety disorders, and depression, continue to grow, adaptogens are emerging as a leading therapeutic remedy. This partnership between Lucy and High Times will enable the two companies to expand the reach of Lucy’s products and promote the potential health benefits to a broader audience.”
We would like to see a clean break above the 20 DMA at $1.63/share.
Recent IPO report on the first psychedelics manufacturing company to be listed on NASDAQ!
Lucy Scientific Discovery Inc. (NASDAQ: LSDI)
Hot sector, building momentum, low float, great setup
Current price $1.39/share as of market close 03/22/23
Public Float 10.15M Shares (Source: Yahoo Finance)
Range Since Inception $1.12 - $4.00/share
About Lucy
Lucy Scientific Discovery Inc. is a Nasdaq-listed (NASDAQ: LSDI) licensed producer of compounds for medicinal products. As granted by Health Canada’s Office of Controlled Substances, Lucy maintains a Controlled Drugs and Substances Dealer’s License, under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s License. A Dealer’s License authorizes LSDI to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors.
Here is What Lucy Offers (Source: https://www.lucyscientific.com/)
API and Target Formulation Production
By leveraging various scalable production methods, Lucy is uniquely positioned to effectively support current and future market needs at competitive prices.
Lucy's use of efficient and strategic manufacturing practices ensure a consistent and stable supply of the highest quality products from lab- to consumer-scale.
Research, Development and Commercialization Support
We will work directly with researchers and finished product manufacturers in a controlled and collaborative environment to facilitate healthy market growth.
Our team aims to maximize your probability of success while minimizing the time and costs required to achieve your goals.
Lucy (LSDI) has announced multiple breaking developments since its IPO last month.
LSDI is “focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry”.
The company’s mission is to make their “products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs including various mental health and addiction disorders”.
As the company stated in a recent press release:
“The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options.”
In addition, as the company explained:
“We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States,” said Chris McElvany, the Company’s CEO.
LSDI is “a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies”.
Furthermore, “The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B”.
The company’s team “is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.”
In addition, the company’s “executive team brings deep experience in the development and commercialization of products featuring controlled substances as well as the navigation of regulatory structures applicable to these products”.
LSDI’s target customers “include an increasing number of the leading universities, hospitals and other public, private, and government institutions throughout the world that have launched research programs to conduct clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances”.
Recently, the company achieved multiple milestones.
On February 13, the company announced:
“Lucy Scientific Discovery Announces Closing of its $7.5 Million Initial Public Offering”
In addition, the company announced:
“Lucy Scientific Discovery to Ring Nasdaq Closing Bell Today in Celebration of its IPO”
Here are the company’s comments from this press release:
“We are excited to celebrate this victory at Nasdaq's iconic bell ringing ceremony, as today marks an important milestone for the Company,” said Chris McElvany, the Company’s CEO. “We are pleased to celebrate many months of hard work and team effort that led to the successful completion of our IPO. Seeing Lucy, a pioneer in psychedelics manufacturing, take the next step in its development by becoming the first psychedelics manufacturing company to be listed on NASDAQ is a huge accomplishment. This milestone marks a significant step in the company's growth and plans for expansion. We look forward to the opportunities ahead of us to continue working on improving mental health and finding sustainable solutions for treatment.”
Afterwards, the company announced another big accomplishment:
“Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin Following Initial Delivery of DMT and 5-MeO-DMT to Hadassah BrainLabs”
Here are the company’s comments from this press release:
“This first commercial sale of psilocybin marks a key operational milestone for the company as we shift from pre revenue to revenue producing, and are excited about further opportunities ahead,” said Lucy’s CEO Chris McElvany. “This transaction establishes Lucy’s ability to supply the global psychedelic community with compounds and services. Not only will it strengthen our relationship with the researchers at Hadassah-Hebrew University Medical Center, whose research helps lay the academic foundations indicating the potential of psychedelics, it will lead to the improvement of lives of millions of people around the world.”
Most recently, on Friday, the company announced another significant development:
“Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities”
As the company further explains:
LSDI “partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies”.
Furthermore:
“By leveraging Pramantha Group's expertise in identifying and capturing strategic funding and contract opportunities, Lucy Scientific is well-positioned to compete for and secure key government contracts and grants. With access to these funds, Lucy Scientific will be able to expand its drug manufacturing capabilities and contribute to the country's healthcare needs.”
Here are some of the company’s comments from this press release:
"Our partnership with Pramantha Group will help us navigate the complex landscape of government contracts and grants and identify the right opportunities to support our growth and contribute to the country's healthcare needs," said Lucy Scientific Discovery’s CEO Chris McElvany. "We are excited to work with Pramantha Group to enhance our drug manufacturing capabilities and play a key role in securing the domestic drug supply. Pramantha has a proven track record and a commitment to excellence that makes it an ideal partner for Lucy as we look to grow our operations."
LSDI has multiple potential catalysts favoring a future of increased growth.
The chart is flashing oversold with an RSI of 35.34
A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD $6,859.95 million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027.
It is important to note that approximately 70% of the psychedelics market is attributable to psychedelics manufacturers.
Full Analysis and Disclosure: https://mailchi.mp/broadstreetalerts/lsdi-lic...s-94477?e=[UNIQID]
(0)
(0)Scroll down for more posts ▼
